A phase 3 randomized, placebo-controlled, triple blind parallel-group study of candesartan in adults with episodic cluster headache (Episodic CandClus2)
interventional
N/A
2 countries
9
The main objective of this study is to assess the prophylactic efficacy of the angiotensin-receptor antagonist candesartan 32 mg compared with placebo in reducing the frequency of severe and very severe CH attacks in participants with episodic cluster headache during a three-week blinded phase, compared to a one-week baseline (pre-randomization diary phase).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 10, 2025
Actual (reported)Change in the weekly frequency of severe and very severe cluster headache attacks from the pre-randomization diary during the three-week blinded phase
Change from baseline in total attack frequency of cluster headache attacks during the three-week blinded phase
50% responder rate (proportion of participants with ≥50% reduction of severe and very severe attacks/week from baseline) over the blinded phase
30% responder rate (proportion of participants with ≥30% reduction of severe and very severe attacks/week from baseline) over the blinded phase
50% responder rate for each week in the blinded phase
Time to sustained freedom of attacks for ≥2 months after the current bout
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Rigshospitalet
Glostrup, 2600, Denmark
Universitetssykehuset Nord-Norge HF
Tromsoe, 9038, Norway
St. Olavs Hospital HF
Trondheim, 7006, Norway
CandClus studiekontakt NorHEAD
NorHEAD Studieinfo
First Submitted
July 10, 2025
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Civamide Nasal Solution for Cluster Headache
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
Contact the study team to confirm eligibility.
Akershus University Hospital
Lorenskog, 1478, Norway
Helse Bergen HF
Bergen, 5021, Norway
Oslo University Hospital HF
Oslo, 0424, Norway
Nordlandssykehuset HF
Bodo, 8005, Norway
Helse Stavanger HF
Stavanger, 4068, Norway
Helse Moere Og Romsdal HF
Aalesund, 6017, Norway